Alkermes Plc Reports Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Alkermes (ALKS) PT Lowered to $47 at Credit Suisse
October 24, 2018 8:54 AM EDTCredit Suisse analyst Vamil Divan lowered the price target on Alkermes (NASDAQ: ALKS) to $47.00 (from $51.00) while maintaining an Outperform rating following Q3.
Divan modestly reduces their sales estimates for Vivitrol and Aristada and also increase some of their expense assumptions... More
Alkermes (ALKS) Tops Q3 EPS by 15c, Revenues Beat; Raises FY18 EPS Guidance
October 23, 2018 7:05 AM EDTAlkermes (NASDAQ: ALKS) reported Q3 EPS of $0.07, $0.15 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $248.7 million versus the consensus estimate of $236.7 million.
"Our solid results in the quarter were in-line with expectations, driven by the growth of our proprietary commercial products, the continued strength of our royalty and manufacturing business, and the important investments we are making in our late-stage pipeline and commercial... More
